HK inno.N Corporation
Works in Cardiovascular · GI & liver · Infectious disease · Metabolic & endocrine · Respiratory
HK inno.N Corporation is a clinical trial sponsor. It has 12 active clinical trials with 6,500 planned participants, across 5 therapeutic areas. Since 2021 it has completed 18 trials and stopped 0 early.
Trial track record · since 2021
Pipeline · 12 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about HK inno.N Corporation
HK inno.N Corporation is lead sponsor of 12 active clinical trials on ClinicalTrials.gov, with 6,500 planned participants, in Cardiovascular, GI & liver, Infectious disease, Metabolic & endocrine and other areas. Since 2021 it has completed 18 trials and stopped 0 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with HK inno.N Corporation; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-01.
Approve Suite is not affiliated with HK inno.N Corporation.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.